ArticleClinical journal of gastroenterology2026
Response to pembrolizumab after progression on durvalumab in cholangiocarcinoma: a case report of immune checkpoint inhibitor switching.
Akito Furuta et al.PubMed ↗Publisher ↗
No numbers read from the abstract.